What Happens When You Stop a GLP-1? Weight Regain, Explained

A GLP-1 is not a course of antibiotics you finish and move on from — it manages an ongoing physiological process, and stopping it is its own decision with its own well-documented consequences. Here is what the trial data actually shows about what happens after you stop.

The extension-trial data: most of the weight comes back

The clearest evidence on this comes from the STEP 1 trial extension, which followed participants who stopped semaglutide after the main trial ended. It found that participants regained roughly two-thirds of their prior weight loss in the year after discontinuation, alongside a reversal of the cardiometabolic improvements — blood pressure, blood sugar and lipid gains — that came with the weight loss¹. That is not a fringe finding; it is the extension of the same pivotal trial cited throughout this site for semaglutide's efficacy, run by the same investigators, on the same cohort. The number to take away is roughly two-thirds, not "all of it" and not "none of it" — genuine partial regain is the documented default when treatment simply stops with no further plan.

Why this happens: it's mechanism, not willpower

GLP-1 medications work by mimicking a gut hormone that affects appetite signaling, satiety and how quickly the stomach empties, among other pathways. Obesity itself involves physiological drivers that outlast any single behavior — the body's regulatory systems tend to defend a prior, higher weight once external appetite suppression is removed, a dynamic well-documented independent of GLP-1 medications specifically. That is the mechanistic reason regain is common when a GLP-1 stops with nothing replacing the appetite-regulation effect it was providing, not a verdict on anyone's discipline.

Discontinuation isn't all-or-nothing — there are documented paths

A 2025 review specifically on discontinuation strategies "while maintaining weight loss" outlines that the outcome depends heavily on how a taper is managed and what replaces the medication's effect — structured dose reduction rather than an abrupt stop, continued behavioral support, resistance training and protein intake (see does a GLP-1 cause muscle loss for why that matters doubly here), and in some cases a switch to a lower maintenance dose rather than a full stop². A broader 2026 review of GLP-1 receptor agonists frames the same point structurally: durability of weight loss is tied to duration and continuity of treatment, consistent with how the drug class works mechanistically rather than as a one-time reset³.

What this means before you stop

If cost is the reason you're considering stopping, that is a real and common driver — see what compounded GLP-1 actually costs per month and the cheapest GLP-1 board before assuming there's no more-affordable way to continue, since switching providers is often cheaper than stopping outright. If you are stopping for another reason, talk to your clinician about a structured taper rather than an abrupt stop, and go in with a plan for the appetite-regulation gap the medication was filling — nutrition, resistance training, and behavioral support are the levers with actual evidence behind them, not a guarantee, but a meaningfully better starting position than stopping cold. The extension-trial and discontinuation-strategy sources above are indexed in our research library. Not medical advice — see our medical disclaimer and talk to a clinician before changing your regimen.